



(43) International Publication Date
8 October 2015 (08.10.2015)

(10) International Publication Number
WO 2015/150254 A1

(51) International Patent Classification:

C07D 403/12 (2006.01) *A61P 25/00* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/EP2015/056713

(22) International Filing Date:

27 March 2015 (27.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2014 00194 4 April 2014 (04.04.2014) DK

(71) Applicant: **H. LUNDBECK A/S** [DK/DK]; Ottiliavej 9,
DK-2500 Valby (DK).

(72) Inventors: **KEHLER, Jan**; Nymøllevej 28, DK-2800 Lyn-
gby (DK). **RASMUSSEN, Lars Kyhn**; Kaløvej 19, DK-
2720 Vanløse (DK). **LANGGÅRD, Morten**; Rågevej 20,
DK-2600 Glostrup (DK).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HALOGENATED QUINAZOLIN-THF-AMINES AS PDE1 INHIBITORS

(57) Abstract: The present invention provides halogenated quinazolin-THF-amines as PDE1 inhibitors and their use as a medica-
ment, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.



WO 2015/150254 A1